ConductScience.org, home

Comparison · NCT03518034-6ae5fbf3

AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. AndroGel 1.62% vs Placebo: Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event. Trial comparisons, record NCT03518034-6ae5fbf3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03518034-6ae5fbf3

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0350.02860.0428wilson
Risk in group 20.02460.01930.0313wilson
Risk difference, group 1 minus group 20.01040.001140.0198newcombe hybrid score
Risk ratio, group 1 over group 21.421.041.95log
Odds ratio, group 1 over group 21.441.041.99log
Number needed to treat, for one more participant with the outcome on AndroGel 1.62% than on Placebo96.250.5876from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AndroGel 1.62%
Participants received topical testosterone starting with a 40.5 mg dose (2 pump actuations) of the study drug OD. Participants may have received a dose in the range of 20.25 mg (1 actuation) to 101.25 mg (5 actuations) in 20.25 mg increments during the course of the study if titrations were necessary.
912,601OG000
Group 2PlaceboParticipants received matching placebo OD.642,603OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Time From Randomization to First Clinical Fracture: Number and Percentage of Participants With an Event
Description
Clinical fracture is defined as a clinical spine or non-spine fracture, documented by imaging or surgery, and confirmed by the Fracture Adjudication Committee (FAC). Fractures of the sternum, fingers, toes, facial bones and skull were excluded.
Time frame
Randomization to event or last known date if no event (up to approximately 52 months).
Population
TRAVERSE Main Study Full Analysis Set: all randomized participants without duplicate/triplicate participant IDs.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
NCT number
NCT03518034
Phases
PHASE4
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Lead sponsor
AbbVie
Results first posted
2024-03-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03518034-6ae5fbf3